NASDAQ:IRON

Disc Medicine (IRON) Stock Price, News & Analysis

$26.62
-0.38 (-1.41%)
(As of 12:02 PM ET)
Today's Range
$26.57
$27.89
50-Day Range
$26.98
$75.32
52-Week Range
$25.60
$77.60
Volume
80,735 shs
Average Volume
419,304 shs
Market Capitalization
$642.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.29

Disc Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
112.2% Upside
$57.29 Price Target
Short Interest
Bearish
7.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Disc Medicine in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$81,408 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.44) to ($5.12) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

415th out of 909 stocks

Pharmaceutical Preparations Industry

185th out of 424 stocks

IRON stock logo

About Disc Medicine Stock (NASDAQ:IRON)

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

IRON Stock Price History

IRON Stock News Headlines

Disc Medicine (NASDAQ:IRON) Stock Price Down 4.1%
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
IRON Sep 2024 60.000 put
IRON Jun 2024 40.000 put
IRON Apr 2024 65.000 call
IRON Apr 2024 40.000 put
See More Headlines
Receive IRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IRON
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$57.29
High Stock Price Target
$85.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+112.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
7 Analysts

Profitability

Net Income
$-76,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.30 per share

Miscellaneous

Free Float
23,003,000
Market Cap
$651.78 million
Optionable
Not Optionable
Beta
0.18
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Donald William Nicholson Ph.D. (Age 65)
    Executive Chairman
    Comp: $164k
  • Dr. William Jacob Savage M.D. (Age 49)
    Ph.D., Chief Medical Officer
    Comp: $687.74k
  • Dr. John D. Quisel Esq. (Age 53)
    J.D., Ph.D., CEO, President & Director
    Comp: $750.12k
  • Dr. Brian MacDonald ChB (Age 64)
    MB, Ph.D., Founder & Chair of Scientific Advisory Board
    Comp: $88.54k
  • Ms. Jean M. Franchi (Age 58)
    Chief Financial Officer
  • Mr. Jonathan Yu M.B.A. (Age 43)
    Chief Opearating Officer
    Comp: $539.32k
  • Dr. Rahul Khara J.D. (Age 42)
    Pharm.D., General Counsel, Compliance Officer & Secretary
  • Mr. Srikanth Venkatraman Ph.D.
    Senior VP & Head of Chemistry
  • Ms. Hua Yang Ph.D.
    Senior Vice President of Nonclinical Development
  • Ms. Pamela Stephenson M.P.H. (Age 55)
    Chief Commercial Officer

IRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Disc Medicine stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IRON shares.
View IRON analyst ratings
or view top-rated stocks.

What is Disc Medicine's stock price target for 2024?

7 Wall Street analysts have issued 1-year price targets for Disc Medicine's shares. Their IRON share price targets range from $40.00 to $85.00. On average, they expect the company's share price to reach $57.29 in the next twelve months. This suggests a possible upside of 112.2% from the stock's current price.
View analysts price targets for IRON
or view top-rated stocks among Wall Street analysts.

How have IRON shares performed in 2024?

Disc Medicine's stock was trading at $57.76 at the start of the year. Since then, IRON stock has decreased by 53.3% and is now trading at $27.00.
View the best growth stocks for 2024 here
.

Are investors shorting Disc Medicine?

Disc Medicine saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,860,000 shares, an increase of 47.6% from the March 15th total of 1,260,000 shares. Based on an average daily volume of 431,300 shares, the days-to-cover ratio is presently 4.3 days.
View Disc Medicine's Short Interest
.

When is Disc Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our IRON earnings forecast
.

How were Disc Medicine's earnings last quarter?

Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.22.

How do I buy shares of Disc Medicine?

Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRON) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners